Regeneron Pharma (REGN) Preannouncement Highlights Evolution Beyond Eylea & Dupixent - RBC
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $679.00 price target on Regeneron Pharma (NASDAQ: REGN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
